베바시주맙 안내주입술로 호전된 하층망막박리를 동반한 중심장액맥락망막병증 1예
A Case of Central Serous Chorioretinopathy Associated With Retinal Detachment Improved by Intravitreal Bevacizumab Injection
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
목적: 만성중심장액맥락망막병증 환자에서 유리체강내 고용량 베바시주맙(2.5 mg) 주입술 후 증상 및 해부학적 호전을 경험하였기에 이를 보고하고자 한다. 증례요약: 중심장액맥락망막병증으로 치료 없이 경과관찰하던 38세 남자 환자가 마지막 외래방문 후 11개월이 지난 뒤 우안의 심한 시력저하를 주소로 내원하였다. 안저검사상 황반부를 침범한 장액망막박리 소견 및 형광안저촬영검사상 다발성 초기 과형광 병변 보 였으며, 빛간섭단층촬영검사상 감각망막박리 및 중심황반두께 증가 소견을 보였다. 만성중심장액맥락망막병증 진단하에 2.5 mg 유리 체강내 베바시주맙 주입술 시행하였고, 주입 2개월 뒤 시력의 호전 및 해부학적인 호전 소견을 보였으며, 이후 6개월간 재발 및 합병증 은 발생되지 않았다.
Abstract
Purpose: To report a case of chronic central serous chorioretinopathy treated with an intravitreal injection of 2.5 mg of bevacizumab. Case summary: A 38-year-old male complained of visual disturbance in the right eye. He had a history of central serous chorioretinopathy which improved without treatment. Since the patient did not feel any ocular discomfort, he did not visit our clinic for approximately 11 months. At the time of presentation, fundus examination revealed exudative retinal detachment involving the macular area. Additionally, fluorescein angiography revealed multiple early phase hyperfluorescent lesions. Neurosensory detachment around the macula and increased central macular thickness were also observed using optical coherence tomography. Under the diagnosis of chronic central serous chorioretinoapthy, the patient was treated with 2.5 mg of intravitreal bevacizumab. Visual acuity improved two months after treatment, with improvement in both neurosensory retinal detachment and fluorescein leakage. No changes were observed at the six-month follow-up.
참고문헌 (15)
- Spitnaz M, "Pathogenesis of central serous chorioretinopathy. A new working hypotheses", Graefes Arch Clin Exp Ophthalmol, 224, pp.321~324 (1986)
- Gass JD, "Pathogenesis of disciform detachment of the neuroepithelium", Am J Ophthalmol, 63(Suppl), pp.1~139 (1967)
- Lafaut BA, "Indocyanine green angiographic is of value for the diagnosis of chronic serous chorioretinopathy in elderly patients", Graefes Arch Clin Exp Ophthalmol, 236, pp.513~521 (1998)
- Piccolion FC, "Indocyanine green angiographic findings in central serous chorioretinopathy", Eye, 9, pp.324~332 (1995)
- Schaal KB, "Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy", Eur J Ophthalmol, 19, pp.613~617 (2009)
- Artunay O, "Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy : A prospective, controlled clinical study", Curr Eye Res, 35, pp.91~98 (2010)
- Seoung HK, "Intravitreal Bevacizumab to treat acute central serous chorioretinopathy: Short-term effect", Ophthalmologica, 223, pp.343~347 (2009)
- Torres-Soriano ME, "A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case report)", Graefes Arch Clin Exp Ophthalmol, 246, pp.1235~1239 (2008)
- Lim SJ, "Intravitreal bevacizumab injection for central serous chorioretinopathy", Retina, 30, pp.100~106 (2010)
- 김마르다, "만성중심장액맥락망막병증에 대한 광역학치료 결과", 대한안과학회지, 50(7), pp.1035~1043 (2009), 대한안과학회
- Guyer DR, "Digital indocyanine green videoangiography of central serous chorioretinopathy", Arch Ophthalmol, 112, pp.1057~1062 (1994)
- Azad RV, "Current and future role of photodynamuc therapy in chronic central serous chorioretinopathy", Am J Ophthalmol, 139, pp.393~394 (2005)
- Colucciello M, "Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy", Retina, 26, pp.239~242 (2006)
- Heiduschka P, "Penetration of bevacizumab through the retina after intravitreal injection in the monkey", Invest Ophthalmol Vis Sci, 48, pp.2814~2823 (2007)
- Amselem L, "Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up", Eye, 21, pp.566~567 (2007)